The mounting evidence that Novo Nordisk’s and Eli Lilly’s blockbuster weight loss drugs provide significant benefits to patients supports even higher prices for the drugs, a major drug pricing watchdog said on Tuesday, in one …
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News



